Can the rs2282679 GT variant contribute to lower vitamin D status?

The rs2282679 single nucleotide polymorphism in the GC gene is a key genetic determinant of vitamin D status, directly influencing how the body transports and maintains circulating vitamin D.

Mechanistic pathway

• Gene expression and DBP concentrations: The rs2282679 variant acts as a regulatory element for the GC gene, which encodes vitamin D-binding protein (DBP). The heterozygous GT genotype results in intermediate GC gene expression and circulating DBP concentrations, situated between high-expression TT and low-expression GG homozygotes.
• Transport capacity: Because DBP serves as the primary carrier transporting approximately 88% of circulating 25-hydroxyvitamin D [25(OH)D], a decrease in its concentration directly reduces the total transport capacity of vitamin D in the bloodstream. This alteration is driven by protein concentration rather than changes to DBP's binding affinity.

Clinical and physiological impact

• Reduced vitamin D status: Individuals carrying the rs2282679 GT variant exhibit moderately lower circulating vitamin D levels. Studies demonstrate a consistent 10% to 20% reduction in total serum 25(OH)D levels per risk allele.
• Insufficiency risk: This genetically driven reduction in DBP concentration and transport capacity shifts baseline vitamin D levels downward, placing carriers at an elevated risk for clinical vitamin D insufficiency or deficiency.

Bottom line

• The rs2282679 GT variant contributes to lower vitamin D status by reducing GC gene expression and circulating DBP levels, which ultimately limits 25(OH)D transport capacity and results in a 10% to 20% reduction in total serum vitamin D levels.